NCT03768505 2024-12-31Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)MEI Pharma, Inc.Phase 2 Terminated169 enrolled 10 charts
NCT04745832 2024-11-04Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)MEI Pharma, Inc.Phase 3 Terminated82 enrolled 11 charts